Hepatocellular carcinoma: Genome-scale metabolic models for hepatocellular carcinoma

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 6, 2014, Pages 336-337

  Pinyol, Roser ^a   Llovet, Josep M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYTOTOXIC AGENT; FOLATE RECEPTOR; FOLIC ACID; FOLIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; PLATINUM COMPLEX; TUBULYSIN B HYDRAZIDE; UNCLASSIFIED DRUG; VINTAFOLIDE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CHOLESTEROL SYNTHESIS; COHORT ANALYSIS; COMPUTER MODEL; DIET; DRUG EFFICACY; GENETIC MODEL; GENOME SCALE METABOLIC MODEL; GENOMICS; HUMAN; IN VIVO STUDY; LIPID METABOLISM; LIPOGENESIS; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; METABOLISM; METABOLITE; NONALCOHOLIC FATTY LIVER; OVARY CANCER; PATHOGENESIS; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; RISK REDUCTION; SEX DIFFERENCE;

ALGORITHMS; CARCINOMA, HEPATOCELLULAR; GENOME; HUMANS; LIVER NEOPLASMS; MODELS, THEORETICAL;

EID: 84901988670     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2014.70     Document Type: Review

References (10)

1. European Association for the Study of the Liver &European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908-943 (2012).
2. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
3. Agren, R. et al. Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol. Syst. Biol. 10, 721 (2014).
4. Notarnicola, M., Tutino, V. &Caruso, M. G. Tumor-induced alterations in lipid metabolism. Curr. Med. Chem. http://dx.doi.org/10.2174/ 0929867321666140303122426.
5. Singh, S., Singh, P. P., Roberts, L. R. &Sanchez, W. Chemopreventive strategies in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 11, 45-54 (2014).
6. Singh, S., Singh, P. P., Singh, A. G., Murad, M. H. &Sanchez, W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144, 323-332 (2013).
7. Tsan, Y. T. et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J. Clin. Oncol. 31, 1514-1521 (2013).
8. Van der Heiden, M. G. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 10, 671-684 (2011).
9. Hoshida, Y. et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 69, 7385-7392 (2009).
10. Mardinoglu, A. et al. Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat. Commun. 5, 3083 (2014).